Accumulating safety data from the large, international ORIGIN trial have been reviewed by its independent data monitoring committee, who have concluded that there is no cause for concern. This six-year study, which is lead by McMaster University professors Dr. Hertzel Gerstein and Dr. Salim Yusuf of the Population Health Research Institute, is determining whether insulin glargine and/or omega 3 fatty acids can reduce cardiovascular events in 12, 578 people with elevated blood sugar levels from around the world. The data monitoring committee, headed by Professor Rory Collins of the University of Oxford, is auditing the trial for safety, but did extra reviews recently after an article in the European journal Diabetologia in June suggested a connection between use of insulin glargine and cancer.
Late-Breaking Clinical Trials Scheduled For Release At The European Society Of Cardiology Congress 2009 In Barcelona
Does Aspirin work for primary prevention? What is the added value of Cardiac Resynchronisation Therapy? Is the future all about biodegradable stents? Come to the ESC Press Conferences and find out about the latest developments in cardiology. The ESC Congress 2009, taking place in Barcelona from 29 August to 2 September, is just a week away. Detailed information for all sessions can already be found in the Scientific Programme Online (SPO): http://spo.escardio.org/Welcome.aspx?eevtid=33. Abstract texts will be posted one week prior to the Congress and the abstracts and slides of Hot Line and Clinical Trial Update presentations will be available on the web immediately after the sessions.
Featured Clinical Trials To Be Presented At Transcatheter Cardiovascular Therapeutics 2009 In San Francisco
Special presentations will be made Sept. 24, 2-6 p.m. WHAT: A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology. WHEN: The TCT Featured Clinical Trials will be presented on September 24, 2009 from 2:00 - 6:00 pm. Session I. Drug-Eluting Stents ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents Cheol Whan Lee, MD CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation Flavio L Ribichini, MD STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina Josef Veselka, MD, PhD NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Randomized Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent John A.
Bristol GPs Report Reduced Hospital Admissions And Improved Care For Patients With Chronic Heart Failure Using Telehealth
GPs at The Orchard Medical Centre in Bristol have reported on the success of telehealth in improving care for patients with chronic heart failure (CHF), keeping them independent and out of emergency care, and promoting greater self-management. The Bristol-based practice has successfully integrated telehealth into its CHF service, to provide more preventative support within the community setting, help avoid hospital admissions and reduce some of the burden on secondary care providers whilst providing a cost-effective model of care for the management of the condition. GPs at the Orchard Medical Centre have liberated valuable additional resource and have reported reduced hospital admissions for some of the CHF patients since deploying the telehealth solutions.
A multidisciplinary team led by Carnegie Mellon University computer scientist Edmund M. Clarke has received a five-year, $10 million grant from the National Science Foundation's Expeditions in Computing program to create revolutionary computational tools that will advance science on a broad array of fronts, from discovering new cancer treatments to designing safer aircraft. The researchers will combine Model Checking and Abstract Interpretation, two methods that have been successful in finding errors in computer circuitry and software, and extend them so they can provide insights into models of complex systems, whether they are biological or electronic.
New research claims that rosiglitazone, a drug used to treat Type 2 diabetes, is associated with an increased risk of heart failure and death among older people compared to a similar drug called pioglitazone. Researchers in Canada compared the risk of heart attack, heart failure and death in people treated with rosiglitazone and pioglitazone. They identified nearly 40, 000 people aged 66 years and older who started treatment with either rosiglitazone or pioglitazone between April 2002 and March 2008. Confirmation of previous studies Dr Iain Frame, Director of Research at Diabetes UK, said: "This is a well-designed retrospective study of older people with Type 2 diabetes using rosiglitazone or pioglitazone.